Nepikastat

Nepikastat
	5-(aminometil)-1-[(2S)-5,7-difluoro-1,2,3,4-tetrahidronaftalen-2-il]-1,3-dihidro-2H-imidazol-2-tion
Drugi nazivi	SYN-117
Identifikacija
CAS registarski broj	173997-05-2
PubChem	9796181
ChemSpider	7971947
MeSH	Nepicastat
Jmol-3D slike	Slika 1
SMILES
	Fc1cc3c(c(F)c1)CC[C@H](N2/C(=C\NC2=S)CN)C3
InChI
	InChI=1S/C14H15F2N3S/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20/h3,5,7,10H,1-2,4,6,17H2,(H,18,20)/t10-/m0/s1 ; Kod: YZZVIKDAOTXDEB-JTQLQIEISA-N InChI=1/C14H15F2N3S/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20/h3,5,7,10H,1-2,4,6,17H2,(H,18,20)/t10-/m0/s1; Kod: YZZVIKDAOTXDEB-JTQLQIEIBJ
Svojstva
Molekulska formula	C14H15F2N3S
Molarna masa	295.35 g/mol
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Nepikastat (INN) (SYN117, RS-25560-197) je enzimski inhibitor dopaminske beta hidroksilaze, enzima koji katalizuje konverziju dopamina u norepinefrin.^[4]

On je je ispitan kao potencijalni lek kongestivno zatajenje srca, i pokazano je da je dobro tolerisan u toj ulozi.^[5] 2012, Klinička ispitivanja koja su istraživala moguću primenu nepikastata u lečenju posttraumatskog stresnog poremećaja (PTSD) i kokainske zavisnosti su završena 2012.^[6]^[7]

Sinteza

Jedan od mogućih sintetičkih puteva je^[8]:

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Stanley WC, Li B, Bonhaus DW, et al. (August 1997). „Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase”. Br J Pharmacol 121 (8): 1803–9. DOI:10.1038/sj.bjp.0701315. PMC 1564872. PMID 9283721.
↑ Hegde SS, Friday KF (December 1998). „Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure”. Current pharmaceutical design 4 (6): 469–79. PMID 10197057.
↑ „Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)”. ClinicalTrials.gov. U.S. National Institutes of Health. 4. 6. 2008.. Retrieved on February 1, 2012.
↑ „Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers”. ClinicalTrials.gov. U.S. National Institutes of Health. 15. 8. 2008.. Retrieved on February 1, 2012.
↑ U.S. Patent 5.719.280

Spoljašnje veze

Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Stanley WC, Li B, Bonhaus DW, et al. (August 1997). „Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase”. Br J Pharmacol 121 (8): 1803–9. DOI:10.1038/sj.bjp.0701315. PMC 1564872. PMID 9283721.

[5] Hegde SS, Friday KF (December 1998). „Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure”. Current pharmaceutical design 4 (6): 469–79. PMID 10197057.

[6] „Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)”. ClinicalTrials.gov. U.S. National Institutes of Health. 4. 6. 2008.. Retrieved on February 1, 2012.

[7] „Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers”. ClinicalTrials.gov. U.S. National Institutes of Health. 15. 8. 2008.. Retrieved on February 1, 2012.

[8] U.S. Patent 5.719.280

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]